Ianalumab (VAY736) Safety and Efficacy in Patients with Sjogren's Syndrome: 52 Week Results from a Randomized, Placebo-controlled, Phase 2b Dose-ranging Trial

被引：0
|
作者：
Doerner, Thomas [1 ,2 ]
Bowman, Simon J. [3 ]
Fox, Robert [4 ]
Mariette, Xavier [5 ]
Papas, Athena [6 ]
Grader-Beck, Thomas [7 ]
Fisher, Ben A. [3 ]
Barcelos, Filipe [8 ]
De Vita, Salvatore [9 ]
Schulze-Koops, Hendrik [10 ]
Moots, Robert [11 ]
Junge, Guido [12 ]
Woznicki, Janice [13 ]
Sopala, Monika [12 ]
Luo, Wen-Lin [13 ]
Hueber, Wolfgang [12 ]
机构：
[1] Charite Univ Med Berlin, Berlin, Germany
[2] Deutsch Rheumaforschszentrum DRFZ, Berlin, Germany
[3] Univ Hosp Birmingham NHS Fdn Trust, Dept Rheumatol, Birmingham, W Midlands, England
[4] Scripps Mem Hosp & Res Inst, San Diego, CA USA
[5] Univ Paris Saclay, Rheumatol, Paris, France
[6] Tufts Sch Dent Med, Div Oral Med, Boston, MA USA
[7] Johns Hopkins Univ, Baltimore, MD USA
[8] Inst Portugues Reumatol, Lisbon, Portugal
[9] Univ Hosp Udine, DAME, Div Rheumatol, Udine, Italy
[10] Univ Munich, Dept Internal Med 4, Div Rheumatol & Clin Immunol, Munich, Germany
[11] Aintree Univ Hosp NHS Fdn Trust, Acad Rheumatol Dept, Liverpool, Merseyside, England
[12] Novartis Pharma AG, Basel, Switzerland
[13] Novartis Pharmaceut, E Hanover, NJ USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2021年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0986
引用
收藏
页码：2063 / 2065
页数：3
相关论文
共 50 条
  • [1] IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN'S SYNDROME: 52 WEEK RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL
    Doerner, T.
    Bowman, S. J.
    Fox, R.
    Mariette, X.
    Papas, A.
    Grader-Beck, T.
    Fisher, B. A.
    Barcelos, F.
    De Vita, S.
    Schulze-Koops, H.
    Moots, R. J.
    Junge, G.
    Woznicki, J.
    Sopala, M.
    Luo, W.
    Hueber, W.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (12) : 87 - 88
  • [2] IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN'S SYNDROME: 52 WEEK RESULTS FROM A RANDOMISED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL
    Dorner, T.
    Bowman, S. J.
    Fox, R.
    Mariette, X.
    Papas, A.
    Grader-Beck, T.
    Fisher, B. A.
    Barcelos, F.
    De Vita, S.
    Schulze-Koops, H.
    Moots, R. J.
    Junge, G.
    Woznicki, J.
    Sopala, M.
    Luo, W. L.
    Hueber, W.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 593 - 594
  • [3] Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial
    Bowman, Simon J.
    Fox, Robert
    Doerner, Thomas
    Mariette, Xavier
    Papas, Athena
    Grader-Beck, Thomas
    Fisher, Benjamin A.
    Barcelos, Filipe
    De Vita, Salvatore
    Schulze-Koops, Hendrik
    Moots, Robert J.
    Junge, Guido
    Woznicki, Janice N.
    Sopala, Monika A.
    Luo, Wen-Lin
    Hueber, Wolfgang
    [J]. LANCET, 2022, 399 (10320): : 161 - 171
  • [4] Iscalimab (CFZ533) in Patients with Sjogren's Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study
    Fisher, Benjamin A.
    Mariette, Xavier
    Papas, Athena S.
    Grader-Beck, Thomas
    Bootsma, Hendrika
    Ng, Wan-Fai
    Van Daele, Paul
    Finzel, Stephanie
    Elgueta, Sergio
    Hermann, Josef
    McCoy, Sara
    Bookman, Arthur
    Sopala, Monika
    Luo, Wen-Lin
    Scheurer, Cornelia
    Hueber, Wolfgang
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 3242 - 3244
  • [5] Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial
    Muir, A.
    Goodman, Z.
    Levy, C.
    Janssen, H.
    Montano-Loza, A.
    Bowlus, C.
    Ding, D.
    Jia, C.
    McColgan, B.
    Myers, R.
    Subramanian, M.
    McHutchison, J.
    Manns, M.
    Chapman, R.
    Afdhal, N.
    Eksteen, B.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S73 - S73
  • [6] Efficacy and safety of povorcitinib for extensive vitiligo: 52-week results from a double-blinded, placebo-controlled, dose-ranging phase 2b study
    Pandya, Amit G.
    Ezzedine, Khaled
    Passeron, Thierry
    van Geel, Nanja
    Brown, Kurt
    Santos, Leandro
    Erskine, Lois
    Wagya, Kofi
    Blauvelt, Andrew
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [7] Linzagolix for treating endometriosis-associated pain: efficacy and safety results from a randomized, placebo-controlled, multinational, phase 2b dose-ranging trial
    Bestel, E.
    Humberstone, A.
    Lecomte, V.
    Dubouloz, R.
    Terrill, P.
    Donnez, J.
    Taylor, H.
    Taylor, R.
    Loumaye, E.
    [J]. HUMAN REPRODUCTION, 2019, 34 : 64 - 64
  • [8] Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study
    Oakes, Tina Marie Myers
    Skljarevski, Vladimir
    Zhang, Qi
    Kielbasa, William
    Hodsdon, Michael E.
    Detke, Holland C.
    Camporeale, Angelo
    Saper, Joel R.
    [J]. CEPHALALGIA, 2018, 38 (06) : 1015 - 1025
  • [9] Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial
    Dubourg, Julie
    Ueki, Kohjiro
    Grouin, Jean-Marie
    Fouqueray, Pascale
    [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (03): : 800 - 810
  • [10] Ianalumab (VAY736), a Dual Mode of Action Biologic Combining BAFF Receptor Inhibition with B Cell Depletion, for Treatment of Primary Sjogren's Syndrome: Results of an International Randomized, Placebo Controlled Dose Range Finding Study in 190 Patients
    Bowman, Simon
    Fox, Robert
    Doerner, Thomas
    Mariette, Xavier
    Papas, Athena
    Grader-Beck, Thomas
    Fisher, Benjamin A.
    Barcelos, Filipe
    De Vita, Salvatore
    Schulze-Koops, Hendrik
    Moots, Robert J.
    Junge, Guido
    Woznicki, Janice
    Sopala, Monika
    Luo, Wen-Lin
    Hueber, Wolfgang
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
12345